The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (DANNOAC-VTE)
Deep Vein Thrombosis, Pulmonary Embolism
About this trial
This is an interventional treatment trial for Deep Vein Thrombosis focused on measuring Non-vitamin K antagonist oral anticoagulation, Non-vitamin K Antagonist Oral Anticoagulants, Direct-acting Oral Anticoagulants, Novel oral anticoagulant drugs
Eligibility Criteria
Inclusion Criteria:
- A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization.
- A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.
Exclusion Criteria:
- A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for VTE.
- Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC.
- Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC.
Sites / Locations
- Aarhus University Hospital
- Bispebjerg HospitalRecruiting
- Amager HospitalRecruiting
- Rigshospitalet
- Bispebjerg and Frederiksberg HospitalRecruiting
- Esbjerg HospitalRecruiting
- Nordsjællands Hospital - FrederiksundRecruiting
- Herlev Gentofte HospitalRecruiting
- Glostrup Hospital - Department of Emergency MedicineRecruiting
- Glostrup Hospital - Department of Medicine / CardiologyRecruiting
- Glostrup Hospital - Department of NeurologyRecruiting
- Herlev-Gentofte Hospital - Department of MedicineRecruiting
- Nordsjællands Hospital - HillerødRecruiting
- Hjørring Hospital
- Holbæk HospitalRecruiting
- Hvidovre HospitalRecruiting
- Næstved Hospital
- Odense University Hospital - Department of CardiologyRecruiting
- Odense University Hospital - Department of Emergency MedicineRecruiting
- Odense University Hospital - Department of GeriatricsRecruiting
- Zealand University Hospital - Department of NeurologyRecruiting
- Zealand University Hospital Roskilde - Department of Cardiology
- Bornhoms HospitalRecruiting
- Slagelse Hospital
- Odense University Hospital SvendborgRecruiting
- Vejle HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Dabigatran
Rivaroxaban
Edoxaban
Apixaban
After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.